Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder Annexon's tanruprubart showed significant and sustained functional gains in Guillain-Barré patients, meeting key Phase 3 trial endpoints.
ANNX Stock Earnings: Annexon Meets EPS for Q2 2024 ANNX stock results show that Annexon met analyst estimates for earnings per share the second quarter of 2024.
ANNX Stock Earnings: Annexon Beats EPS for Q1 2024 ANNX stock results show that Annexon beat analyst estimates for earnings per share the first quarter of 2024.
ANNX Stock Earnings: Annexon Beats EPS for Q4 2023 ANNX stock results show that Annexon beat analyst estimates for earnings per share the fourth quarter of 2023.
7 Top Stocks Under $10: June 2024 Edition While blue-chip stocks are great, it's also a good idea to invest in top stocks under $10 to help improve your portfolio's diversification.
Mid-Cap Firm Annexon's Nerve Disorder Candidate Shows Promise In Pivotal Late-Stage Study Annexon reports positive Phase 3 trial results for ANX005 in Guillain-Barré syndrome, showing significant improvements in disability, muscle strength, and ventilation duration.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday It's time to start Tuesday with a breakdown of the biggest pre-market stock movers traders will want to know about this morning!
Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of Cutera, Inc. (
NASDAQ: CUTR ) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results.
